| Name | Value |
|---|---|
| Revenues | 533.3M |
| Cost of Revenue | 364.3M |
| Gross Profit | 169.0M |
| Operating Expense | 56.7M |
| Operating I/L | 112.3M |
| Other Income/Expense | 6.5M |
| Interest Income | 7.5M |
| Pretax | 118.8M |
| Income Tax Expense | 22.4M |
| Net Income/Loss | 96.4M |
Medpace Holdings, Inc. provides comprehensive clinical research-based drug and medical device development services globally. The company offers a range of services supporting the clinical development process from Phase I to Phase IV across various therapeutic areas. Its services include clinical development, project management, regulatory affairs, data management and analysis, pharmacovigilance, new drug application submissions, and post-marketing clinical support. Additionally, it provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace generates revenue by offering these services to pharmaceutical, biotechnology, and medical device industries.